Should a patient with rheumatoid arthritis be a kidney donor?

• Published in: Clinical rheumatology 2019-01, Vol.38 (1), p.251-256
• Main Authors: Seto, Richard, Mathias, Lauren M., Kelly, Andrew, Panush, Richard S.
• Format: Article
• Language: English
• Subjects: Acetaminophen; Amyloidosis; Anti-inflammatory agents; Autonomy; Case Based Review; Cyclosporins; Decision making; End-stage renal disease; Epidermal growth factor receptors; Ethics; Hydroxychloroquine; Inflammation; Kidney diseases; Medicine; Medicine & Public Health; Methotrexate; Nephritis; Nonsteroidal anti-inflammatory drugs; Organ donors; Patients; Remission; Rheumatoid arthritis; Rheumatology; Sjogren's syndrome; Surgery; Vasculitis
• ISSN: 0770-3198; 1434-9949
• DOI: 10.1007/s10067-018-4350-5

We cared for a woman with sero-positive rheumatoid arthritis (RA), in clinical remission on oral methotrexate (MTX) and hydroxychloroquine, who wished to donate a kidney to a brother with end-stage renal disease (ESRD). We could find scant literature about this unusual clinical circumstance, and therefore review pertinent aspects of renal disease in RA, perioperative medical management, maintenance of disease remission, outcomes for RA patients who have donated kidneys, and relevant ethical issues. Renal complications in RA are not uncommon, with as many as 50% of patients at risk of reduced eGFR. This reflects anti-rheumatic and analgetic medication use (non-steroidal anti-inflammatory drugs, acetaminophen, DMARDs [cyclosporine and, historically, d -penicillamine and gold compounds], and others), glomerulitis, interstitial nephritis, complicating Sjogren’s syndrome, vasculitis, or amyloidosis, and/or emergence of an “overlap” syndrome or other rheumatic disorder. The literature suggests that MTX need not be interrupted for surgery. The risk of perioperative infection to our patient would be low and remission should be sustained. We are aware of one study of six patients with RA who donated kidneys; they experienced no complications, ESRD, or deaths after a median follow-up of 8.2 years. Our ethical responsibilities are to balance patient autonomy of decision-making while assuring clinical beneficence and minimizing potential maleficence. Our perspective was that it would not be unreasonable to support this patient donating a kidney if, when fully informed, that remained her wish.